Clinical Trial Update: Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating blinatumomab for refractory myasthenia gravis, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Zhongming Qiu | Conditions: Myasthaenia Gravis | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING